Summary
DHR Chart
Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved safety profile of Aldveron's Nanoplasmidâ„¢ vector technology and the gentle gene-delivery of Kytopen's Flowfect Txâ„¢ platform with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields.
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y
DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.
Danaher Corporation (DHR) Q1 2025 Earnings Call Transcript
Danaher Corporation (NYSE:DHR ) Q1 2025 Earnings Conference Call April 22, 2025 8:00 AM ET Company Participants John Bedford - VP, IR Rainer Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Michael Ryskin - Bank of America Tycho Peterson - Jefferies Scott Davis - Melius Research Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Rachel Vatnsdal - JPMorgan Daniel Brennan - TD Cowen Daniel Arias - Stifel Operator My name is Chelsy, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's First Quarter 2025 Earnings Results Conference Call.
Danaher Corporation Dividends
 DHR In 1 month Estimated | Quarterly | $0.32 Per Share |
| DHR 1 month ago Paid | Quarterly | $0.32 Per Share |
| DHR 4 months ago Paid | Quarterly | $0.27 Per Share |
| DHR 7 months ago Paid | Quarterly | $0.27 Per Share |
| DHR 10 months ago Paid | Quarterly | $0.27 Per Share |
| DHR 27 Mar 2024 Paid | Quarterly | $0.27 Per Share |
Danaher Corporation Earnings
| 21 Apr 2025 Date | | - Cons. EPS | - EPS |
| 29 Jan 2025 Date | | 2.14 Cons. EPS | 2.14 EPS |
| 28 Jan 2025 Date | | 2.14 Cons. EPS | - EPS |
| 22 Oct 2024 Date | | 1.57 Cons. EPS | 1.71 EPS |
| 23 Jul 2024 Date | | 1.57 Cons. EPS | 1.72 EPS |
| DHR In 1 month Estimated | Quarterly | $0.32 Per Share |
| DHR 1 month ago Paid | Quarterly | $0.32 Per Share |
| DHR 4 months ago Paid | Quarterly | $0.27 Per Share |
| DHR 7 months ago Paid | Quarterly | $0.27 Per Share |
| DHR 10 months ago Paid | Quarterly | $0.27 Per Share |
| DHR 27 Mar 2024 Paid | Quarterly | $0.27 Per Share |
| 21 Apr 2025 Date | | - Cons. EPS | - EPS |
| 29 Jan 2025 Date | | 2.14 Cons. EPS | 2.14 EPS |
| 28 Jan 2025 Date | | 2.14 Cons. EPS | - EPS |
| 22 Oct 2024 Date | | 1.57 Cons. EPS | 1.71 EPS |
| 23 Jul 2024 Date | | 1.57 Cons. EPS | 1.72 EPS |
Danaher Corporation (DHR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Danaher Corporation ever had a stock split?
Danaher Corporation Profile
| Diagnostics & Research Industry | Healthcare Sector | Mr. Steven M. Rales CEO | BVL Exchange | US2358511028 ISIN |
| US Country | 61,000 Employees | 28 Mar 2025 Last Dividend | 2 Oct 2023 Last Split | 5 Jan 1979 IPO Date |
Overview
Danaher Corporation is a global powerhouse in the design, manufacturing, and marketing of a vast array of professional, medical, industrial, and commercial products and services. With its inception in 1969 and a significant rebranding in 1984, where it transitioned from Diversified Mortgage Investors, Inc. to Danaher Corporation, the company has established a formidable presence in various sectors. Headquartered in Washington, D.C., Danaher stands out through its commitment to innovation, excellence, and enhancing the quality of life worldwide.
Products and Services
- Biotechnology: Danaher's biotechnology segment is a provider of bioprocess technologies, consumables, and services enhancing the development and manufacture of therapeutics. This includes cell line and cell culture media development, chromatography resins, filtration technologies, aseptic fill-finish solutions, single-use hardware, and comprehensive services aimed at setting up full manufacturing suites.
- Life Sciences: This segment delivers a wide range of products including mass spectrometers, flow cytometry, genomics solutions, lab automation instruments, centrifugation, liquid handling automation instruments, antibodies and reagents, particle counting and characterization tools, microscopes, and protein consumables. Among the notable brands under the Life Sciences segment are ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX, each providing specialized products for genomic medicines and industrial filtration.
- Diagnostics: Danaher’s diagnostics sector offers a comprehensive range of chemistry, immunoassay, microbiology, automation systems, molecular diagnostics, acute care, and pathology diagnostics products. Aimed at hospitals, physicians' offices, reference laboratories, and other critical care settings, this segment ensures the delivery of clinical instruments, reagents, consumables, software, and dedicated services to support critical diagnostics.
Contact Information
